18791 - Sun Protection Factor Assay
Not Applicable
Completed
- Conditions
- Sunscreening Agent
- Interventions
- Drug: Coppertone (BAY987517)
- Registration Number
- NCT02682628
- Lead Sponsor
- Bayer
- Brief Summary
To evaluate the Sun Protection Factor (SPF) efficacy on human skin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
- Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
- Male and female
- Aged between 18-70 years old.
- Good health as determined from the HRL SHF
- Signed and dated Informed Consent Form
- Signed and dated HIPAA Form
- An unbmbiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose)
Exclusion Criteria
- Subjects on test at any other research laboratory or clinic.
- Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
- Pre-existing dermatologic conditions which have been dianoses by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
- Pre-existing other medical conditions (e.g. adult asthma. diabetes).
- Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
- Treatment with antibiotics within two weeks prior to initiation of the test.
- Chronic medication which could affect the results of the study.
- Known pregnant or nursing women.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description BAY987517 Coppertone (BAY987517) Each test site area is divided into test subsite areas that are approximately at least 0.5 cm\*2. The application of test material is 2 mg/cm\*2. Thus, each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
- Primary Outcome Measures
Name Time Method Minimal Persistent Pigment DArkening Dose (MPPD) Up to 15 minutes Minimal Erythema Dose (MED) Up to 15 minutes
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie BAY987517's photoprotective efficacy in SPF assays?
How does Coppertone (BAY987517) compare to standard UV filters in UVA protection factor (UVAPF) and MPPD outcomes?
Are there biomarkers like skin phototype or melanin content that predict SPF efficacy of BAY987517 in clinical trials?
What adverse events are associated with BAY987517 application, and how do they compare to Bayer's other sunscreen formulations?
How does BAY987517's UVA/UVB protection profile compare to competitor products like avobenzone or zinc oxide in vivo?